NICE Guidance - February 2016
The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of February 2016. This month there is one technology appraisal and six clinical guidelines that impact upon primary care.
The Ezetimibe technology appraisal recommends this treatment as monotherapy as an option for people with primary (heterozygous‑familial or non‑familial) hypercholesterolaemia who have a contraindication to or cannot tolerate a statin. It is also recommended for co-administration with a statin when cholesterol targets are not being met despite maximal statin therapy or when a change from initial statin therapy to an alternative statin is being considered.
The Motor neurone disease clinical guideline covers the assessment and management of motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care and includes recommendation on recognition and referral.
The Sunlight exposure clinical guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency. This guideline was also used to update the Skin cancer prevention public health guidance.
The Tuberculosis clinical guideline received a correction regarding identification of babies eligible for vaccination prior to birth, ideally through antenatal services.
The Bipolar disorder clinical guideline received an update to include a link to the Medicines and Healthcare Products Regulatory Agency’s (MHRA) toolkit to ensure female patients are better informed about the risks of taking valproate during pregnancy.
The Epilepsies clinical guideline received an update to include a link to the Medicines and Healthcare Products Regulatory Agency’s (MHRA) toolkit to ensure female patients are better informed about the risks of taking valproate during pregnancy.
The Attention deficit hyperactivity disorder clinical guideline received an update to the recommendations on dietary advice.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
| « Drug Safety Update - February 2016 | SMC Update - March 2016 » |
Leave a Comment